In vivo CAR-T engineering: insights from the 2025 ASH annual meeting.

Gelayol Asadi1,2, Misagh Rajabinejad3

  • 1Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

PubMed
Summary

In vivo chimeric antigen receptor (CAR)-T cell engineering shows promise for cancer treatment by reprogramming T-cells. Recent advancements highlight efficient CAR expression and tumor clearance, though challenges remain for future studies.